A first systematic review, investigating the efficacy of S-adenosylmethionine within the early weeks of treatment in adults with intrahepatic cholestasis (IHC), has been recently published on World Journal of Hepatology. Noureddin M. et al.Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol.
Data from both randomised and non-randomised studies suggest that SAMe improves some biochemical liver parameters and symptoms of cholestasis within 2 weeks, with further improvements observed in some studies after 4 and 8 weeks of treatment.
IHC is the impairment of bile formation or bile flow resulting from hepatocellular functional defects or obstructive lesions of the intrahepatic biliary tract. It is associated with clinical signs and symptoms such as pruritus, jaundice, and fatigue, which may subsequently be associated with depression, autonomic dysfunction, and sleep disturbances. SAMe is a natural compound, synthesised and metabolised mainly by the liver via multiple pathways; it is likely that exogenous SAMe is rapidly metabolised, improving overall liver metabolic homeostasis.
"SAMe controls many vital hepatic functions as well as the response to liver injury. This is a very positive review which can encourage further studies and the use SAMe in liver health disorders," said Lorena Carboni, Product Manager of the branded S-adenosylmethionine Adonat of Gnosis by Lesaffre.
